ALL-TK inhibitors (SUGEN)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameALL-TK inhibitors (SUGEN)
Drug Alias Nameacute lymphocytic leukemia tyrosine kinase inhibitors (SUGEN)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJanus kinase inhibitors
TargetsJanus kinase
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSugen Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSugen Llc
Active IndicationsN/A
Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A